Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

  1. Morales-Cano, D.
  2. Izquierdo-García, J.L.
  3. Barreira, B.
  4. Esquivel-Ruiz, S.
  5. Callejo, M.
  6. Pandolfi, R.
  7. Villa-Valverde, P.
  8. Rodríguez, I.
  9. Cogolludo, A.
  10. Ruiz-Cabello, J.
  11. Perez-Vizcaino, F.
  12. Moreno, L.
Zeitschrift:
Frontiers in Pharmacology

ISSN: 1663-9812

Datum der Publikation: 2023

Ausgabe: 14

Art: Erratum

DOI: 10.3389/FPHAR.2023.1228923 GOOGLE SCHOLAR lock_openOpen Access editor

Ziele für nachhaltige Entwicklung

Datenquelle: Scopus